

Nemaura Medical Inc

09:45 03 Mar 2020

Nemaura launches sugarBEAT app on Google's Play Store ahead of BEAT diabetes subscription service

Nemaura Medical Inc (NASDAQ:NMRD), the maker of the sugarBEAT continuous glucose monitor, said Tuesday that it has launched its sugarBEAT app for Android devices on the Play Store to prep for the launch of the company's BEAT diabetes subscription-based service expected next month.

"We believe that the launch of our app is a big step towards our commercial milestones, and we are looking forward to launching the BEAT diabetes subscription service shortly during Type 2 Diabetes Prevention Week in the UK. This is a very exciting time in our company's development," said Nemaura CEO Faz Chowdhury in a statement.

"The sugarBEAT app includes time-in-range profiling features which we believe is rapidly being adopted as the primary metric for managing individual daily blood glucose profiles," he added.

READ: Nemaura's exciting 2Q sets it up to execute commercial strategy for sugarBEAT

The digital health offering, BEAT diabetes, help patients with prediabetes and Type 2 diabetes by empowering them with tools to better manage, prevent and potentially even reverse their condition. The digital health offering is a subscription-based service.

The full range of subscription-based services includes an app that makes lifestyle recommendations based on blood glucose levels, offers one-on-one coaching and routinely measures other parameters that allow improved disease management.

Both BEAT diabetes and the sugarBEAT monitor itself serve the underserved \$69 billion market for Type 2 diabetics and \$50 billion market for pre-diabetics.

The Loughborough, UK-based medtech company launched shipments of its sugarBEAT, the world's first painless glucose monitor, to patients in August 2019 in the UK. The wave of shipments was Nemaura's first foray into the European market after receiving its CE mark, an EU seal of approval, in May 2019.

"The UK licensee of SugarBEAT, DB Ethitronix, is currently in the process finalizing the launch of online sales of sugarBEAT," said the company.


Nemaura is planning to initiate a user study comparing its sugarBEAT continuous glucose monitor (CGM) directly against a highly successful major incumbent CGM sensor. The company's goal with the study is to position sugarBEAT as a non-invasive, daily/flexible, cost-effective alternative to traditional, expensive invasive CGMs.

sugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. The genius of SugarBEAT lies in its skin-patch

Price: 8.57

Market Cap: \$179.65 m

1 Year Share Price Graph



July 2019 December 2019 July 2020

Share Information

Code: NMRD

Listing: NASDAQ

52 week	High	Low
	16.35	2.5

Sector: Medical technology & services

Website: www.nemauramedical.com

Company Synopsis:

Nemaura Medical Inc. is a medical technology company which has developed sugarBEAT® as a non-invasive, affordable and flexible continuous glucose monitor (CGM) designed to improve glucose management for all people with diabetes and pre-diabetics.

action@proactiveinvestors.com

technology which allows for better glucose management.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Nemauro Medical Inc named herein, including the promotion by the Company of Nemauro Medical Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).